The study by Ezaz et al. showed a clinically useful model where patients with HER2-positive breast cancer were divided into low, medium and high-risk groups for heart failure/cardiomyopathy, with relatively good discriminative ability [15]. This evidence concerns the gene ERBB2 and heart failure.